Company: CMND
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005519
Chunk: 16

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: POS AM
Chunk 16
---
 coverage or the coverage might not suffice to cover potential
damages. Any losses or damages incurred by us could have a material adverse effect on our business.

Finally, political conditions within Israel
may affect our operations. Israel has held five general elections between 2019 and 2022, and prior to October 2023, the Israeli government
pursued extensive changes to Israel’s judicial system, which sparked extensive political debate and unrest. To date, these initiatives
have been substantially put on hold. Actual or perceived political instability in Israel or any negative changes in the political environment,
may individually or in the aggregate adversely affect the Israeli economy and, in turn, our business, financial condition, results of
operations and growth prospects.

<div align='center'>5

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

This prospectus and elsewhere, including in
our 2024 Annual Report incorporated by reference herein, and other information included or incorporated by reference in this prospectus,
contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans,
objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that
are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking
statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,”
“continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,”
“may,” “objective,” “plan,” “predict,” “potential,” “positioned,”
“seek,” “should,” “target,” “will,” “would,” and other similar expressions
that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.
These forward-looking statements include, but are not limited to, statements about:

| ● | the                                                                                           
 ability of our pre-clinical and any future clinical trials to demonstrate safety and efficacy 
 of our future product candidates, and other positive results;                                 |

| ● | the                                                                                       
 timing and focus of our future preclinical studies and clinical trials, and the reporting 
 of data from those studies and trials;                                                    |

| ● | the size of the market opportunity                                                                                                  
 for our future product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; |

| ● | the success of competing therapies that are or may